Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
Jonas Bergh(Karolinska Institutet), Nils Wilking(Sophiahemmet Hospital), Jonas Nilsson(Regional Research Council in Uppsala-Örebro Region), S. Ottosson(Sahlgrenska University Hospital), Carl Blomqvist(University of Helsinki), Henrik Lindman(Uppsala University), Elisabet Lidbrink(Stockholm South General Hospital), Per Ljungman(Karolinska University Hospital), Harald Holte(Oslo University Hospital), Per Malmström, Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), Gustaf Söderlund(Linköping University Hospital), Nils‐Olof Bengtsson, Björn Erikstein, Erik Wist(Oslo University Hospital), Gun Anker(Haukeland University Hospital), Eeva Salminen(University of Turku), Tom Wiklund(Lund University)
Cited by 343
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k